TABLE 2.

Health and Economic Results of Screening Interventions for a Population of 100,000 Adults

Strategy	Cost	QALYs	Cirrhosis	Decompensated Cirrhosis	HCC	Transplants	HBV Deaths
Heplisav-B
Status quo	407,218,391	2,377,829	461	131	431	156	690
HBsAg + Vacc	367,022,663	2,380,014	323	84	341	123	526
HBsAg, anti-HBs + Vacc	365,641,803	2,380,014	323	84	341	123	526
HBsAg, anti-HBs, anti-HBc + Vacc	365,591,884	2,380,014	323	84	341	123	526
Engerix-B/Recombivax HB
Status quo	405,264,020	2,377,824	462	131	431	156	690
HBsAg + Vacc	365,073,912	2,380,009	324	84	341	123	527
HBsAg, anti-HBs + Vacc	363,727,272	2,380,009	324	84	341	123	527
HBsAg, anti-HBs, anti-HBc + Vacc	363,683,205	2,380,009	324	84	341	123	527
Twinrix
Status quo	408,974,805	2,377,824	462	131	431	156	690
HBsAg + Vacc	368,650,275	2,380,009	324	84	341	123	527
HBsAg, anti-HBs + Vacc	366,485,066	2,380,009	324	84	341	123	527
HBsAg, anti-HBs, anti-HBc + Vacc	366,300,996	2,380,009	324	84	341	123	527

Cost: in US dollars. Dominant: the intervention has lower costs and higher QALYs than the status quo.

ICER indicates incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.